Results 191 to 200 of about 25,184 (248)
Some of the next articles are maybe not open access.

Diffuse midline glioma: review of epigenetics

Journal of Neuro-Oncology, 2020
Our understanding of diffuse midline glioma (DMG) biology inclusive of diffuse intrinsic pontine glioma has been revolutionized by the discovery of novel mutations on the tails of histone 3, leading to the reclassification in 2016 of 'diffuse midline glioma, H3 K27M-mutant.' Given the abundance of basic, translational, and clinical information put ...
Tabitha M. Cooney   +4 more
openaire   +2 more sources

Diffuse Midline Glioma – Diffuse Intrinsic Pontine Glioma

2020
Diffuse midline glioma, H3 K27M-mutant, formerly known as diffuse intrinsic pontine glioma (DIPG), is a malignant and infiltrative neoplasm of the pons. DIPG mainly affects the pediatric population and is associated with dismal prognosis, where less than 10% of sufferers survive beyond 2 years from diagnosis.
Mohammad Hassan A. Noureldine   +2 more
openaire   +1 more source

Antisense oligonucleotide therapy for H3.3K27M diffuse midline glioma

Science Translational Medicine, 2023
Diffuse midline gliomas (DMGs) are pediatric high-grade brain tumors in the thalamus, midbrain, or pons; the latter subgroup are termed diffuse intrinsic pontine gliomas (DIPG). The brain stem location of these tumors limits the clinical management of DIPG, resulting in poor outcomes for patients.
Qian Zhang   +4 more
openaire   +2 more sources

ONC201-Derived Tetrahydropyridopyrimidindiones as Powerful ClpP Protease Activators to Tackle Diffuse Midline Glioma.

Journal of Medicinal Chemistry
Pediatric diffuse intrinsic pontine glioma (DIPG), classified under diffuse midline glioma, is a deadly tumor, with no effective treatments. The human mitochondrial protease hClpP is a potential DIPG therapeutic target, and this study describes the ...
Morena Miciaccia   +19 more
semanticscholar   +1 more source

A comprehensive multicenter analysis of clinical, molecular, and imaging characteristics and outcomes of H3 K27-altered diffuse midline glioma in adults.

Journal of Neurosurgery
OBJECTIVE The objective was to comprehensively investigate the clinical, molecular, and imaging characteristics and outcomes of H3 K27-altered diffuse midline glioma (DMG) in adults. METHODS Retrospective chart and imaging reviews were performed in 111
Yongsik Sim   +10 more
semanticscholar   +1 more source

H3F3A K27M mutations drive a repressive transcriptome by modulating chromatin accessibility independent of H3K27me3 in Diffuse Midline Glioma

Epigenetics & Chromatin
Heterozygous histone H3.3K27M mutation is a primary oncogenic driver of Diffuse Midline Glioma (DMG). H3.3K27M inhibits the Polycomb Repressive Complex 2 (PRC2) methyltransferase activity, leading to global reduction and redistribution of the repressive ...
Suraj Bhattarai   +7 more
semanticscholar   +1 more source

H3K27M diffuse midline glioma is homologous recombination defective and sensitized to radiotherapy and NK cell-mediated antitumor immunity by PARP inhibition.

Neuro-Oncology
BACKGROUND Radiotherapy (RT) is the primary treatment for diffuse midline glioma (DMG), a lethal pediatric malignancy defined by histone H3 lysine 27-to-methionine (H3K27M) mutation.
Yupei Guo   +20 more
semanticscholar   +1 more source

Blood-brain barrier opening with neuronavigation-guided focused ultrasound in pediatric patients with diffuse midline glioma.

Science Translational Medicine
Focused ultrasound (FUS)-mediated blood-brain barrier (BBB) opening with microbubbles is an emerging technology that enables drug delivery for central nervous system diseases. To date, most clinical trials assessing BBB opening in adults were designed to
Cheng-Chia Wu   +30 more
semanticscholar   +1 more source

Multi-omics landscape of alternative splicing in diffuse midline glioma reveals immune- and neural-driven subtypes with implications for spliceosome-targeted therapy

Frontiers in Immunology
Introduction H3K27-altered diffuse midline glioma (DMG) is a highly aggressive glioma subtype, accounting for approximately 60% of pediatric high-grade gliomas, with a median survival of less than 12 months.
Chaxian Liu   +9 more
semanticscholar   +1 more source

[Diffuse midline glioma].

No shinkei geka. Neurological surgery, 2022
Diffuse midline glioma(DMG), H3 K27M-mutant is an infiltrative midline high-grade glioma with predominantly astrocytic differentiation and a K27M mutation in either H3F3A or HIST1H3B/C. It is commonly located in the brain stem, thalamus, and spinal cord. DMG is predominant in children but can occur in adults.
openaire   +1 more source

Home - About - Disclaimer - Privacy